Announced Fri, 7 Aug · 11:55 IST
Q1 FY27 results: revenue up 21%, but loss narrows to Rs 38.9 lakh
Revenue Growth 20pctPat NegativeGoing ConcernContingent Liabilities IncreasedAuditor Mid Year ChangeResults View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.7%1-day move
₹2.86
prior close
₹2.99
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+0.0+0.0-2.3+1.7+2.4+3.8+4.2-4.2-0.3+1.4-5.9——
Up moveDown movePending
AI summary
Transgene Biotek reported Q1 FY27 revenue of Rs 6 lakh, up 21% from Rs 4.95 lakh last year. Loss narrowed to Rs 38.90 lakh vs Rs 43.37 lakh. Total expenses of Rs 44.90 lakh include finance costs of Rs 28.95 lakh. Auditor Vasavi and Co gave an unqualified limited review. Board appointed new internal auditor and extended AGM date. Pending matters include NCLT, SAT, ED Tribunal, and a court order to pay Rs 92.99 lakh in the Nitin Didwania case.
Likely market impact
Persistent losses with expenses far exceeding revenue raise going concern worries; multiple legal cases ongoing.